Back to search

Article

Comparison of efficacy and safety of first-line treatment options for unresectable stage III non-small cell lung cancer: a retrospective analysis

2023-11-28

Abstract excerpt

<title>Abstract</title> <p> <bold>Background:</bold> Based on PACIFIC trail, durvalumab as consolidation therapy following concurrent chemoradiotherapy (cCRT) has been a new standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). In clinical applications, there are heterogeneous adjustments or novel strategies following specialized discussions in experienced multidisciplinary teams. Th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2f91f6d7-8dbd-55ee-9a41-a6b28e6ea681
DOI
10.21203/rs.3.rs-3402054/v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparison of efficacy and safety of first-line treatment options for unresectable stage III non-small cell lung cancer: a retrospective analysisDOI 10.21203/rs.3.rs-3402054/v2
Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.Semantic proximity
Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer.Semantic proximity
Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.Semantic proximity
[Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations].Semantic proximity
Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China.Semantic proximity
A Study on the Efficacy of Immune Checkpoint Inhibitors Combined with Chemotherapy in Patients with Oligometastatic Driver Gene-Negative Non-Small Cell Lung Cancer Undergoing RadiotherapySemantic proximity
Efficacy of First-Third generation EGFR inhibitor combined with chemotherapy as first-line treatment for advanced lung adenocarcinoma in a real-world settingSemantic proximity
Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non-Small-Cell Lung Cancer: The JIPANG Study Protocol.Semantic proximity
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.Semantic proximity
Efficacy and safety of first-line treatments for patients with advanced epidermal growth factor receptor mutated non-small cell lung cancer: a network meta- analysisSemantic proximity
Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer.Semantic proximity
Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations.Semantic proximity
Select a neighboring publication to make it the new centre.